Support to help you on your treatment journey
Pay as little as $10* for Teva's Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use
*Offer covers commercially insured patients only.
Please note, this offer is not available for patients eligible for Medicare, Medicaid, or any other form of government insurance. Out-of-pocket costs may vary based on insurance coverage. Limitations apply. See full Terms and Conditions for eligbility restrictions.
Savings Program Terms and Conditions
Terms, Conditions, and Eligibility Requirements: Eligible patients must have commercial prescription insurance with coverage for Teva’s Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use. Uninsured and cash-paying patients are NOT eligible for this Program. Patients enrolled in any state or federally funded healthcare program, including but not limited to, Medicare, Medigap, Medicaid, VA, DOD, TRICARE, Puerto Rico Government Health Insurance Plan, Medicare-eligible patients enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees, are NOT eligible for this Program. Cash Discount Cards and other noninsurance plans are not valid as primary under this Program. This Program is restricted to residents of the United States and United States territories.
Patients may pay as little as $10 out of pocket for Teva’s Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use. Maximum Program assistance per prescription and annual benefits apply and out-of-pocket expenses may vary. Patient is responsible for costs above maximum benefit amounts. This Program is not insurance. Void if copied, transferred, purchased, altered, or traded and where prohibited and restricted by law. The Program is not transferable. No substitutions are permitted. The Program form may not be sold, purchased, traded, or counterfeited. Void if reproduced. The Program benefit cannot be combined with any other financial assistance program, free trial, discount, prescription savings card, or other offer. This Program is managed by Mercalis on behalf of Teva Pharmaceuticals USA, Inc. Teva Pharmaceuticals USA, Inc. and its affiliates reserves the right to make eligibility determinations, to set Program benefit maximums, to monitor participation, and to change, rescind, revoke, or discontinue this Program at any time without notice. Limit one Program enrollment per individual. If you have any questions regarding this Program, your eligibility or benefits, or if you wish to discontinue your participation, please call 844-248-7949. Expiration Date: 12/31/2024.
Valid only for Teva’s Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, National Drug Codes: 00480-9257-08, 00480-9259-08, and 00480-9262-08
To the Patient: By redeeming this Program, you acknowledge that you are an Eligible Patient and you understand and agree to comply with the terms and conditions of this Program.
This Program is for eligible Commercially Insured Patients only. Patients may pay as little as $10 out of pocket for Teva’s Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use. Maximum Program assistance per prescription and annual benefits apply and out-of-pocket expenses may vary. This Program must be presented along with your prescription for Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use and your primary insurance card to participate in this Program. Program not valid for Non-Insured/Cash-Paying Patients or where Teva’s Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use is not covered by the primary insurance.
To the Pharmacist: When you apply this Program, you are certifying that Teva’s Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use is being dispensed to an Eligible Patient in compliance with these terms and conditions and the Pharmacy has not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental program for this prescription. For Commercially Insured Patients, please submit this claim to the primary Third-Party Payer first, then submit the balance due to Mercalis as a Secondary Payer COB (coordination of benefits) with patient responsibility and a valid Other Coverage Code (e.g., 08).
Reimbursement will be received from Mercalis. For questions regarding processing, please call the Help Desk at 844-248-7949.
Important Safety Information
What is the most important information I should know about octreotide acetate for injectable suspension?
Treatment with octreotide acetate for injectable suspension may affect gallbladder function, with reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Tell your doctor if you experience signs or symptoms of gallstones or any of their complications.
Patients with carcinoid tumors and VIP-secreting tumors should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.
Patients with acromegaly should adhere to their return visit schedule to help assure steady control of GH and IGF-1 levels.
What should I tell my doctor before taking octreotide acetate for injectable suspension?
Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.
What are the possible side effects of octreotide acetate for injectable suspension?
In acromegalic patients, the most common side effects of octreotide acetate for injectable suspension include gallstones, diarrhea, abdominal pain, gas, flu-like symptoms, constipation, headache, low red blood cells, injection-site pain, gallstones, high blood pressure, dizziness and fatigue.
In carcinoid tumor and VIP-secreting tumor patients, the most common side effects of octreotide acetate for injectable suspension include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.
These are not all of the possible side effects of octreotide acetate for injectable suspension. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
What is octreotide acetate for injectable suspension?
Octreotide acetate for injectable suspension is a prescription medication used in patients in whom initial treatment with octreotide acetate injection has been shown to be effective and tolerated for:
- Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy, is not an option to reduce GH and IGF-1 levels to normal.
- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors.
In patients with carcinoid tumors and VIP-secreting tumors, the effect of octreotide acetate injection and octreotide acetate for injectable suspension on tumor size, rate of growth and development of metastases, has not been determined.
Please see the full Prescribing Information.